L-Arginine promotes gut hormone release and reduces food intake in rodents

Aims: To investigate the anorectic effect of L‐arginine (L‐Arg) in rodents. Methods: We investigated the effects of L‐Arg on food intake, and the role of the anorectic gut hormones glucagon‐like peptide‐1 (GLP‐1) and peptide YY (PYY), the G‐protein‐coupled receptor family C group 6 member A (GPRC6A) and the vagus nerve in mediating these effects in rodents. Results: Oral gavage of L‐Arg reduced food intake in rodents, and chronically reduced cumulative food intake in diet‐induced obese mice. Lack of the GPRC6A in mice and subdiaphragmatic vagal deafferentation in rats did not influence these anorectic effects. L‐Arg stimulated GLP‐1 and PYY release in vitro and in vivo. Pharmacological blockade of GLP‐1 and PYY receptors did not influence the anorectic effect of L‐Arg. L‐Arg‐mediated PYY release modulated net ion transport across the gut mucosa. Intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) administration of L‐Arg suppressed food intake in rats. Conclusions: L‐Arg reduced food intake and stimulated gut hormone release in rodents. The anorectic effect of L‐Arg is unlikely to be mediated by GLP‐1 and PYY, does not require GPRC6A signalling and is not mediated via the vagus. I.c.v. and i.p. administration of L‐Arg suppressed food intake in rats, suggesting that L‐Arg may act on the brain to influence food intake. Further work is required to determine the mechanisms by which L‐Arg suppresses food intake and its utility in the treatment of obesity

Sequentially based analysis versus image based analysis of Intima Media Thickness in common carotid arteries studies - Do major IMT studies underestimate the true relations for cardio- and cerebrovascular risk?

<p>Abstract</p> <p>Background</p> <p>Image-based B-mode ultrasound has gained popularity in major studies as a non-invasive method of measuring cardio- and cerebrovascular risk factors. However, none of the major studies appears to have paid sufficient attention to the variation in end diastolic wall process. By using sequentially based analyses (SBA) of Intima-Media Thickness (IMT), the general purpose of this study was to show that the current image based (ECG tracked) analysis (IBA) has some major variations and might underestimate the true relations for cardiovascular events and stroke for IMT measurement.</p> <p>Method</p> <p>The study group consisted of 2500 healthy male subjects aged between 35 to 55 years. 4 sequences (300 images) were analyzed per subject. 750,000 images were analysed throughout the course of this study.</p> <p>Results</p> <p>IBA showed significantly lower mean, maximal, and minimal values for IMT in CCA than for SBA. The correlation analysis between IBA and SBA with the cardio- and cerebrovascular risk factors showed a higher correlation of SBA for all risk factors. The Pearson coefficient was 0.81, p < 0.01, for SBA versus Framingham CHD risk level (FCRL) and 0.49, p = 0.01, for IBA versus FCRL.</p> <p>Conclusion</p> <p>IBA did not measure the true maximal values of the IMT in this study. Together with the correlation analysis, this indicates that IBA might underestimate the true relations for IMT and risk factors.</p

An entropy test for single-locus genetic association analysis

<p>Abstract</p> <p>Background</p> <p>The etiology of complex diseases is due to the combination of genetic and environmental factors, usually many of them, and each with a small effect. The identification of these small-effect contributing factors is still a demanding task. Clearly, there is a need for more powerful tests of genetic association, and especially for the identification of rare effects</p> <p>Results</p> <p>We introduce a new genetic association test based on symbolic dynamics and symbolic entropy. Using a freely available software, we have applied this entropy test, and a conventional test, to simulated and real datasets, to illustrate the method and estimate type I error and power. We have also compared this new entropy test to the Fisher exact test for assessment of association with low-frequency SNPs. The entropy test is generally more powerful than the conventional test, and can be significantly more powerful when the genotypic test is applied to low allele-frequency markers. We have also shown that both the Fisher and Entropy methods are optimal to test for association with low-frequency SNPs (MAF around 1-5%), and both are conservative for very rare SNPs (MAF<1%)</p> <p>Conclusions</p> <p>We have developed a new, simple, consistent and powerful test to detect genetic association of biallelic/SNP markers in case-control data, by using symbolic dynamics and symbolic entropy as a measure of gene dependence. We also provide a standard asymptotic distribution of this test statistic. Given that the test is based on entropy measures, it avoids smoothed nonparametric estimation. The entropy test is generally as good or even more powerful than the conventional and Fisher tests. Furthermore, the entropy test is more computationally efficient than the Fisher's Exact test, especially for large number of markers. Therefore, this entropy-based test has the advantage of being optimal for most SNPs, regardless of their allele frequency (Minor Allele Frequency (MAF) between 1-50%). This property is quite beneficial, since many researchers tend to discard low allele-frequency SNPs from their analysis. Now they can apply the same statistical test of association to all SNPs in a single analysis., which can be especially helpful to detect rare effects.</p

Signalling plasticity and energy saving in a tropical bushcricket

Males of the tropical bushcricket Mecopoda elongata synchronize their acoustic advertisement signals (chirps) in interactions with other males. However, synchrony is not perfect and distinct leader and follower roles are often maintained. In entrainment experiments in which conspecific signals were presented at various rates, chirps displayed as follower showed notable signal plasticity. Follower chirps were shortened by reducing the number and duration of syllables, especially those of low and medium amplitude. The degree of shortening depended on the time delay between leader and follower signals and the sound level of the entraining stimulus. The same signal plasticity was evident in male duets, with the effect that the last syllables of highest amplitude overlapped more strongly. Respiratory measurements showed that solo singing males producing higher chirp rates suffered from higher metabolic costs compared to males singing at lower rates. In contrast, respiratory rate was rather constant during a synchronous entrainment to a conspecific signal repeated at various rates. This allowed males to maintain a steady duty cycle, associated with a constant metabolic rate. Results are discussed with respect to the preference for leader signals in females and the possible benefits males may gain by overlapping their follower signals in a chorus

Conceptual Framework for Managing Uncertainty in a Collaborative Agri-Food Supply Chain Context

[EN] Agri-food supply chains are subjected to many sources of uncertainty. If these uncertainties are not managed properly, they can have a negative impact on the agri-food supply chain (AFSC) performance, its customers, and the environment. In this sense, collaboration is proposed as a possible solution to reduce it. For that, a conceptual framework (CF) for managing uncertainty in a collaborative context is proposed. In this context, this paper seeks to answer the following research questions: What are the existing uncertainty sources in the AFSCs? Can collaboration be used to reduce the uncertainty of AFSCs? Which elements can integrate a CF for managing uncertainty in a collaborative AFSC? The CF proposal is applied to the weather source of uncertainty in order to show its applicability.The first author acknowledges the partial support of the Program of Formation of University Professors of the Spanish Ministry of Education, Culture, and Sport (FPU15/03595). The other authors acknowledge the partial support of the Project 691249, RUC-APS: Enhancing and implementing Knowledge based ICT solutions within high Risk and Uncertain Conditions for Agriculture Production Systems, funded by the EU under its funding scheme H2020-MSCA-RISE-2015.Esteso-Álvarez, A.; Alemany Díaz, MDM.; Ortiz Bas, Á. (2017). Conceptual Framework for Managing Uncertainty in a Collaborative Agri-Food Supply Chain Context. IFIP Advances in Information and Communication Technology. 506:715-724. https://doi.org/10.1007/978-3-319-65151-4_64S715724506Taylor, D.H., Fearne, A.: Towards a framework for improvement in the management of demand in agri-food supply chains. Supply Chain Manag. Int. J. 11, 379–384 (2006)Matopoulos, A., Vlachopoulou, M., Manthou, V., Manos, B.: A conceptual framework for supply chain collaboration: empirical evidence from the agri-food industry. Supply Chain Manag. Int. J. 12, 177–186 (2007)Ahumada, O., Villalobos, J.R.: Application of planning models in the agri-food supply chain: a review. Eur. J. Oper. Res. 196, 1–20 (2009)Tsolakis, N.K., Keramydas, C.A., Toka, A.K., Aidonis, D.A., Iakovou, E.T.: Agrifood supply chain management: a comprehensive hierarchical decision-making framework and a critical taxonomy. Biosyst. Eng. 120, 47–64 (2014)van der Vorst, J.G., Da Silva, C.A., Trienekens, J.H.: Agro-industrial supply chain management: Concepts and applications. FAO (2007)Borodin, V., Bourtembourg, J., Hnaien, F., Kabadie, N.: Handling uncertainty in agricultural supply chain management: a state of the art. Eur. J. Oper. Res. 254, 348–359 (2016)van der Vorst, J.G.A.J., Beulens, A.J.M.: Identifying sources of uncertainty to generate supply chain redesign strategies. Int. J. Phys. Distrib. Logist. Manag. 32, 409–430 (2000)Klosa, E.: A concept of models for supply chain speculative risk analysis and management. J. Econ. Manag. 12, 45–59 (2013)Samson, S., Reneke, J.A., Wiecek, M.M.: A review of different perspectices on uncertainty and risk and an alternative modeling paradigm. Reliab. Eng. Syst. Saf. 94, 558–567 (2009)Backus, G.B.C., Eidman, V.R., Dijkhuizen, A.A.: Farm decision making under risk and uncertainty. Neth. J. Agric. Sci. 45, 307–328 (1997)van der Vorst, J.G.: Effective food supply chains; Generating, modelling and evaluating supply chain scenarios. (2000)Amorim, P., Günther, H.O., Almada-Lobo, B.: Multi-objective integrated production and distribution planning of perishable products. Int. J. Prod. Econ. 138, 89–101 (2012)Amorim, P., Meyr, H., Almeder, C., Almada-Lobo, B.: Managing perishability in production-distribution planning: a discussion and review. Flex. Serv. Manuf. 25, 389–413 (2013)Costa, C., Antonucci, F., Pallottino, F., Aguzzi, J., Sarria, D., Menesatti, P.: A review on agri-food supply chain traceability by means of RFID technology. Food Bioprocess Technol. 6, 353–366 (2013)Pahl, J., Voss, S.: Integrating deterioration and lifetime constraints in production and supply chain planning: a survey. Eur. J. Oper. Res. 238, 654–674 (2014)Grillo, H., Alemany, M.M.E., Ortiz, A.: A review of Mathematical models for supporting the order promising process under Lack of Homogeneity in product and other sources of uncertainty. Comput. Ind. Eng. 91, 239–261 (2016)Zwietering, M.H., van’t Riet, K.: Modelling of the quality of food: optimization of a cooling chain. In: Management Studies and the Agri-business: Management of Agri-chains, Wageningen, The Netherlands, pp. 108–117 (1994)Akkerman, R., Farahani, P., Grunow, M.: Quality, safety and sustainability in food distribution: a review of quantitative operations management approaches and challenges. Spectrum 32, 863–904 (2010)Apaiah, R.K., Hendrix, E.M.T., Meerdink, G., Linnemann, A.R.: Qualitative methodology for efficient food chain design. Trends Food Sci. Technol. 16, 204–214 (2005)Lehmann, R.J., Reiche, R., Schiefer, G.: Future internet and the agri-food sector: State-of-the-art in literature and research. Comput. Electron. Agric. 89, 158–174 (2012)Kusumastuti, R.D., van Donk, D.P., Teunter, R.: Crop-related harvesting and processing planning: a review. Int. J. Prod. Econ. 174, 76–92 (2016)Dreyer, H.C., Strandhagen, J.O., Hvolby, H.H., Romsdal, A., Alfnes, E.: Supply chain strategies for speciality foods: a Norwegian case study. Prod. Plan. Control 27, 878–893 (2016)Baghalian, A., Rezapour, S., Farahani, R.Z.: Robust supply chain network design with service level against disruptions and demand uncertainties: a real-life case. Eur. J. Oper. Res. 227, 199–215 (2013)Aggarwal, S., Srivastava, M.K.: Towards a grounded view of collaboration in Indian agri-food supply chains: a qualitative investigation. Br. Food J. 115, 1085–1106 (2016)Teimoury, E., Nedaei, H., Ansari, S., Sabbaghi, M.: A multi-objective analysis for import quota policy making in a perishable fruit and vegetable supply chain: a system dynamics approach. Comput. Electron. Agric. 93, 37–45 (2013)Opara, L.U.: Traceability in agriculture and food supply chain: a review of basic concepts, technological implications, and future prospects. J. Food Agric. Environ. 1, 101–106 (2003)Kruize, J.W., Wolfert, S., Goense, D., Scholten, H., Beulens, A., Veenstra, T.: Integrating ICT applications for farm business collaboration processes using Fl Space. In: 2014 Annual SRII Global Conference, pp. 232–240. IEEE (2014)Oriade, C.A., Dillon, C.R.: Developments in biophysical and bioeconomic simulation of agricultural systems: a review. Agric. Econ. 17, 45–58 (1997)Camarinha-Matos, L.M., Afsarmanesh, H.: Collaborative networks: value creation in a knowledge society. In: Wang, Kesheng, Kovacs, G.L., Wozny, Michael, Fang, Minglun (eds.) PROLAMAT 2006. IIFIP, vol. 207, pp. 26–40. Springer, Boston, MA (2006). doi: 10.1007/0-387-34403-9_4Prima Dania, W.A., Xing, K., Amer, Y.: Collaboration and sustainable agri-food supply chain: a literature review. MATEC Web Conf. 58 (2016)Simatupang, T.M., Sridharan, R.: The collaborative index: a measure for supply chain collaboration. Int. J. Phys. Distrib. Logist. Manag. 35, 44–62 (2005)Fischer, C., Hartmann, M., Reynolds, N., Leat, P., Revoredo-Giha, C., Henchion, M., Albisu, L.M., Gracia, A.: Factors influencing contractual choice and sustainable relationships in European agri-food supply chains. Eur. Rev. Agric. Econ. 36, 541–569 (2009

Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system- (CNS-) infection that typically occurs in a subset of immunocompromised individuals. An increasing incidence of PML has recently been reported in patients receiving monoclonal antibody (mAb) therapy for the treatment of autoimmune diseases, particularly those treated with natalizumab, efalizumab and rituximab. Intracellular CD4(+)-ATP-concentration (iATP) functionally reflects cellular immunocompetence and inversely correlates with risk of infections during immunosuppressive therapy. We investigated whether iATP may assist in individualized risk stratification for opportunistic infections during mAb-treatment. METHODOLOGY/PRINCIPAL FINDINGS: iATP in PHA-stimulated, immunoselected CD4(+)-cells was analyzed using an FDA-approved assay. iATP of mAb-associated PML (natalizumab (n = 8), rituximab (n = 2), efalizumab (n = 1)), or other cases of opportunistic CNS-infections (HIV-associated PML (n = 2), spontaneous PML, PML in a psoriasis patient under fumaric acids, natalizumab-associated herpes simplex encephalitis (n = 1 each)) was reduced by 59% (194.5±29 ng/ml, mean±SEM) in comparison to healthy controls (HC, 479.9±19.8 ng/ml, p<0.0001). iATP in 14 of these 16 patients was at or below 3(rd) percentile of healthy controls, similar to HIV-patients (n = 18). In contrast, CD4(+)-cell numbers were reduced in only 7 of 15 patients, for whom cell counts were available. iATP correlated with mitochondrial transmembrane potential (ΔΨ(m)) (iATP/ΔΨ(m)-correlation:tau = 0.49, p = 0.03). Whereas mean iATP of cross-sectionally analysed natalizumab-treated patients was unaltered (448.7±12 ng/ml, n = 150), iATP was moderately decreased (316.2±26.1 ng/ml, p = 0.04) in patients (n = 7) who had been treated already during the pivotal phase III trials and had received natalizumab for more than 6 years. 2/92 (2%) patients with less than 24 months natalizumab treatment revealed very low iATP at or below the 3(rd) percentile of HC, whereas 10/58 (17%) of the patients treated for more than 24 months had such low iATP-concentrations. CONCLUSION: Our results suggest that bioenergetic parameters such as iATP may assist in risk stratification under mAb-immunotherapy of autoimmune disorders

Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign

Abstract Background The province of Ontario, Canada initiated mass immunization clinics with adjuvanted pandemic H1N1 influenza vaccine in October 2009. Due to the scale of the campaign, temporal associations with Guillain-Barré syndrome (GBS) and vaccination were expected. The objectives of this analysis were to estimate the number of background GBS cases expected to occur in the projected vaccinated population and to estimate the number of additional GBS cases which would be expected if an association with vaccination existed. The number of influenza-associated GBS cases was also determined. Methods Baseline incidence rates of GBS were determined from published Canadian studies and applied to projected vaccine coverage data to estimate the expected number of GBS cases in the vaccinated population. Assuming an association with vaccine existed, the number of additional cases of GBS expected was determined by applying the rates observed during the 1976 Swine Flu and 1992/1994 seasonal influenza campaigns in the United States. The number of influenza-associated GBS cases expected to occur during the vaccination campaign was determined based on risk estimates of GBS after influenza infection and provincial influenza infection rates using a combination of laboratory-confirmed cases and data from a seroprevalence study. Results The overall provincial vaccine coverage was estimated to be between 32% and 38%. Assuming 38% coverage, between 6 and 13 background cases of GBS were expected within this projected vaccinated cohort (assuming 32% coverage yielded between 5-11 background cases). An additional 6 or 42 cases would be expected if an association between GBS and influenza vaccine was observed (assuming 32% coverage yielded 5 or 35 additional cases); while up to 31 influenza-associated GBS cases could be expected to occur. In comparison, during the same period, only 7 cases of GBS were reported among vaccinated persons. Conclusions Our analyses do not suggest an increased number of GBS cases due to the vaccine. Awareness of expected rates of GBS is crucial when assessing adverse events following influenza immunization. Furthermore, since individuals with influenza infection are also at risk of developing GBS, they must be considered in such analyses, particularly if the vaccine campaign and disease are occurring concurrently

Erythropoietin Ameliorates Rat Experimental Autoimmune Neuritis by Inducing Transforming Growth Factor-Beta in Macrophages

Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role in erythropoiesis. In addition, in various preclinical models EPO exhibited protective activity against tissue injury. There is an urgent need for potent treatments of autoimmune driven disorders of the peripheral nervous system (PNS), such as the Guillain-Barré syndrome (GBS), a disabling autoimmune disease associated with relevant morbidity and mortality. To test the therapeutic potential of EPO in experimental autoimmune neuritis (EAN) - an animal model of human GBS – immunological and clinical effects were investigated in a preventive and a therapeutic paradigm. Treatment with EPO reduced clinical disease severity and if given therapeutically also shortened the recovery phase of EAN. Clinical findings were mirrored by decreased inflammation within the peripheral nerve, and myelin was well maintained in treated animals. In contrast, EPO increased the number of macrophages especially in later stages of the experimental disease phase. Furthermore, the anti-inflammatory cytokine transforming growth factor (TGF)-beta was upregulated in the treated cohorts. In vitro experiments revealed less proliferation of T cells in the presence of EPO and TGF-beta was moderately induced, while the secretion of other cytokines was almost not altered by EPO. Our data suggest that EPO revealed its beneficial properties by the induction of beneficial macrophages and the modulation of the immune system towards anti-inflammatory responses in the PNS. Further studies are warranted to elaborate the clinical usefulness of EPO for treating immune-mediated neuropathies in affected patients

Current treatment practice of Guillain-Barré syndrome

Objective: To define the current treatment practice of Guillain-Barré syndrome (GBS). Methods: The study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account. Results: We excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE. Conclusions: In current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations